Autologous Dendritic Cell Vaccine in Kidney Cancer
Status:
Not yet recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to estimate the probability of immune response for the
combination treatment of dendritic cell vaccine with oral cabozantinib and characterize the
safety profile of interventional therapy.